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Stress resistance capacity is a hallmark of longevity protection and survival throughout the plant and animal kingdoms.
Latent pathway activation of protective cascades, triggered by environmental challenges to tolerate heat, oxygen deprivation,
reactive oxygen species (ROS), diet restriction, and exercise provides tolerance to these stresses. Age-related changes and disease
vulnerability mark an increase in damage, like damage induced by environmental challenges. An alternative approach to
immunotherapy intervention in Alzheimer’s Disease is the use of mimetics of stress to upregulate endogenous protective cascades
to repair age damage, shift the balance of apoptosis to regeneration to promote delay of onset, and even progression of Alzheimer’s
disease memory dysfunction. Mimetics of environmental stress, hormetic agents, and triggers, endogenous or engineered, can
“trick” activation of expression patterns of repair and rejuvenation. Examples of known candidate triggers of heat response,
endogenous antioxidants, DNA repair, exercise, hibernation, and telomeres are available for AD intervention trials. Telomeres and
telomerase emerge as major regulators in crossroads of senescence, cancer, and rejuvenation responsive to mimetics of telomeres.
Lessons emerge from transgenic rodent models, the long-lived mole rat, clinical studies, and conserved innate pathways of stress
resistance. Cross-reaction of beneﬁts of diﬀerent triggers promises intervention into seemingly otherwise unrelated diseases.
1.Introduction
Divergent biological phenomena have fundamental conver-
gent pathways that aﬀect aging, age-related diseases, and
stress resistance responses. Hormetic stress pathways are
activated by environmental chemical and physical cues,
that are beneﬁcial at threshold low levels but are oth-
erwise toxic agents at higher levels [1]. Nature preserves
those organisms and small molecular triggers that pro-
mote tolerance responses to environmental stress including,
youthful restoration of DNA repair, resistance to oxidizing
agents, protein structure and function repair, improved
immunity, tissue remodeling, and altered metabolism [2].
Survival pathways in ancient species exist in present species
and when activated, show potential for increased longevity
and latent rejuvenation potential regardless of divergence of
thehormeticstressingagent.EnvironmentalstressofUVand
p h o t o r e a c t i o n ,a c t i v a t e ss u r v i v a lp a t h w a y st or e j u v e n a t ec e l l s
and increase lifespan in paramecia [3], and induces radiation
resistance and DNA repair in human cells in culture [4].
Common key regulators and pathways respond to diverse
challenges of physical and chemical stresses of temperature,
diet, exercise, hibernation, and radiation. Both posttrans-
lational and transcriptional activation of latent pathways
responsesinvolvesepigeneticmodiﬁcationsbydeacetylation,
phosphorylation, methylation, ubiquitination, and mecha-
nisms used in diﬀerentiation to provide stress resistance.
As a consequence of common protective pathways, cross-
resistance to pathologies that share common cellular cues
represents an under-used strategy in disease intervention;
that is, drugs eﬀective in divergent diseases may show beneﬁt
in acute and chronic dysfunctions and have application in
intervention in Alzheimer’s disease.
The goal of intervention strategy reviewed here is to
decrease vulnerability and rescue in Alzheimer’s disease, by
activation of stress resistance pathways. Triggers mimic envi-
ronmental stresses including oligonucleotides, heat shock,
exercise, and hibernation drugs, known to activate key2 International Journal of Alzheimer’s Disease
regulators of protective metabolic pathways to restore home-
ostasis, and proposed to provide resistance and repair of
oxidative DNA and protein damage induced by AD.
This review focus is on lessons learned from the role of
stress resistance triggers, hormesis, and telomeres, in rodent
models of induced senescence, successful aging in the mole
rat, and obstacles encountered in immunological therapy in
clinical studies to provide a basis for intervention strategy for
AD.
2. Mimetics of Stress Resistance
Stress resistance is key for survival and maintenance of the
species, and nature has preserved survival pathways from
single cells to man. Since the appropriate threshold of low-
dose beneﬁcial versus toxic dose of environmental and
chemical stress is diﬃcult to assess, the use of mimetic agents
of these stresses oﬀers better dosage control to avoid high-
dose stress damage [2]. Mimetics can trigger stress-related
transcriptomes, expression of families of genes activated by
a common transcription factor, that provide beneﬁt not
only the targeted beneﬁcial response, but also youthful reju-
venation, and improvement of multiple avenues to stress
resistance to intervene in multiple age-related disease [5–
7]. These fundamental survival pathways, lifespan assurance
loci, master regulators, also called vitagenes, confer plasticity
to species longevity, lifespan extension, rejuvenation, and
repair [2, 5–12]. As the molecular roles of aging, stress
andneurodegenerativediseaseareelucidated,oxidativestress
emerges as a common damage denominator and activation
of pathways used in early development; that is, FOXO and
IGF-1, also serve roles in mitigation of stress resistance and
disease [13–15].
3. RadiationStress
Mimetics of UV damage include the use of DNA oligonu-
cleotides homologous to the telomere (TTAGGG repeat, “T-
oligo’s”) as triggers to activate innate telomere-based protec-
tive responses that act to reduce DNA and oxidative damage
to cells [4]. The antioxidative pathways induction, by T-
oligo’s, makes these UV mimetics potential candidates for
relieffrominducedoxidativetoxicityinADandcancer.More
recently, telomere homolog oligonucleotides show induction
of apoptosis in malignant, and not normal lymphoid cells, to
provide potential anticancer therapy potential [16].
4. ProteinStructureand Function
Stress Damage
Protein misfolding and aggregation from single cells to mul-
ticellular organisms dramatically aﬀect normal cell structure
and function needed for survival [17] and is a hallmark of
AD.Therescueofneuronproteindamageinvolvesactivation
of the heat shock response, and FOXO, and SIRT-1 to restore
protein homeostasis [18, 19]. Protein homeostasis (pro-
teostasis) is achieved by how high the threshold of the stress
response is set to detect and combat protein misfolding. The
heat shock factor 1 (HSF1) regulates the response to the
metabolic state of the cell and centralized neuronal control
that allows optimal resource allocation between cells and
tissues. HSF1 activation requires a stress-activated NAD+-
dependent SIRT1 deacetylase and phosphorylation, to signal
transcriptionofmolecularchaperonesthatresolvemisfolded
a n da g g r e g a t e dp r o t e i n s[ 19]. Misfolded proteins, whether a
consequence of aging, toxins, hypoxic, oxidative, or ischemic
stress, signal cell death damage, proapoptosis responses, that
impact longevity, and disease states. HSP 70 heat shock
protein is a major rescue response to damage that impacts
longevity [20, 21], vulnerability, and progression of AD neu-
ronal pathology. Hormetic agents are candidates to intervene
in proteotoxic damage and associated clinical symptoms
[22, 23] and are identiﬁed here.
Ethanol is a candidate hormetic trigger to induce the
heat shock response [23] and thus has potential for inter-
vention in AD. Ethanol preconditioning inhibits amyloid-
Beta-induced neurotoxicity and apoptosis [24]. Constitutive
and inducible HSP70s are involved in oxidative resis-
tance evoked by heat shock and ethanol. In the brain,
moderate ethanol pretreatment causes an almost 3-fold
increase in brain levels of heat shock protein HSP 70
and can prevent beta-amyloid peptide (Abeta)-induced
neurotoxicity and apoptosis in organotypic hippocampal-
entorhinal slice cultures [24]. Neuronal protection by
ethanol pretreatment reduces behavioral deﬁcit, neuronal
death, and delays neuronal death, neuronal and dendritic
degeneration, oxidative DNA damage, and glial-cell acti-
vation after ischemia/reperfusion (I/R) challenge [25]a n d
prevents postischemic leukocyte-endothelial cell-adhesive
interactions [26].
Another trigger of protection against oxidative damage
known to induce endogenous antioxidants and HSP70 is
an acyclic isoprenoid. Geranylgeranylacetone (GGA) is a
nontoxic HSP70 inducer of HSP70 with beneﬁcial responses
including reduction of inﬂammation in gastritis, apoptosis,
induction of protective pathways like thioredoxin, and
antiviralgenesthatoﬀerageneralizedupregulationofdisease
immunity [27, 28].
Activation of endogenous antioxidants is an alternative
approach to upregulate natural defenses against oxidative
damage and associated pathologies of neurodegenerative
disease and including AD. Activators of the “Antioxidant
Response Element” include oltipraz, and ferritins. Oltipaz is
a substituted 1,2-dithiole-3-thione, originally developed as
an antischistosomal agent, that possesses chemopreventive
activity by transcriptional activation of a gene cascades
involved in carcinogen detoxiﬁcation and attenuation of
oxidative stress [29]. Exposure of rodents to 1,2-dithiole-3-
thiones trigger nuclear accumulation of the transcription
factor Nrf2 and its enhanced binding to the “antioxidant re-
sponse element” (ARE).
Ferritins, an ancient family of protein nanocages, also
participate in activation of the ARE-responsive element.
Ferritins concentrate iron in iron-oxy minerals for iron-
protein biosynthesis and protection against oxy radical
damage. The promoter of human ferritin-L contains an
overlapping Maf recognition element (MARE) antioxidantInternational Journal of Alzheimer’s Disease 3
responsive element (ARE). Thoreductase can be transcrip-
tionally activated by sulphorane and other electophiles by
the antioxidant response element ARE. The ferritin receptor
is activated by tert-butylhydroquinone, sulforaphane, and
hemin with responses comparable to thioredoxin reductase,
ARE regulator or quinone reductase (MARE/ARE regulator)
[30].
5. Hibernationand AD Intervention
Hibernation is a classical beneﬁcial response to environmen-
tal stresses of depleted energy stores, intracellular acidosis,
hypoxia, hypothermia, cell volume shifts, and inactivity in-
duced muscle wasting [31] characterized by epigenetic mod-
ulation aﬀecting transcriptional and translational controls
[32, 33]. Animals do not need to undergo a torpor state, to
beneﬁt from activation of at least some of the hibernation
protective pathways. Use of Hibernation Induction Triggers,
identiﬁed to activate protective hibernation gene cascades,
especially using deltorphins opioid receptor agonists as
mimetics of hibernation, shows reduction of damage in
rodent model systems of heart attack [7], stroke, and hem-
orrhage shock [34–39]. The cardioprotective mechanism
of deltorphin II is mediated via stimulation of peripheral
delta (2) opioid receptors that involve protein kinase C,
NO-synthase, KATP, and the autonomic nervous system to
induce both its infarct-sparing and antiarrhythmic eﬀects
[37]. Neuroprotection by both hibernating woodcock serum
and deltophin E was demonstrated in an neuronal ischemic
stress rodent model [38]. The delta-2 opioid receptor agonist
activationofprotectivepathwaysincludesanti-inﬂammatory
properties [39] that likely contribute to proven resistance to
shock, that may also reduce AD pathology and progression.
Metabolic changes also characterize hibernation. Upreg-
ulation of fatty acid-binding proteins during hibernation
facilitates the switch to a primary dependence on lipid fuels
by nearly all organs. Changes in hibernation include upreg-
ulation of key regulators of energy metabolism and mito-
chondrial biogenesis, namely, PPAR gamma transcription
factor and its coactivator, PGC-1. Several hypoxia-related
genes including HIF-1alpha are also upregulated during
hibernation suggesting a role for this transcription factor
in mediating adaptive metabolic responses for hibernation
[32, 33] useful in intervention potential for AD and diabetes.
AICAR, (Aminoimidazole-4-carboxamide-1-β-4-
ribofuranoside) an agonist of AMPK, is a mimetic of exercise
that upregulates pathways common to exercise including
the key PGC-1 energy regulator [40]. In theory, and in
experimental studies, AICAR intervenes in acute ischemic
stress, by activation of protective pathways that are anti-
inﬂammatory, anti-oxidative stress, and prosurvival path-
ways that promote intervention in ischemic stress pathways
induced by exercise. Indeed, in our recent studies, AICAR
pretreatment and posttreatment signiﬁcantly increases tol-
erance and survival to a severe hemorrhage model of is-
chemic stress [41].
AICAR is a very promising candidate for pretreatment
of early and late AD since evidence shows that AICAR treat-
ment increased PGC-1alpha as a mimetic of stress. Increases
PGC-1 levels dramatically protect neural cells in culture
from oxidative-stressor-mediated death and making PGC-1
a target molecule for therapeutic manipulation oxidative
stress [42] and candidate target molecule in AD therapy.
AICAR intervenes in LPS/A beta-induced inﬂammatory
processes by blocking the expression of proinﬂammatory
cytokines, inhibits reactive oxygen species in astroglial cells,
and promotes NGF-induced neurite growth in PC-12 cells
[43]. PGC-1 is identiﬁed as a target molecule for diabetes as
well [44].
Related studies use nutritional supplements to increase
heat shock proteins and key metabolic regulators. Acetyl-L-
carnitine induces upregulation of heat shock proteins and
protects cortical neurons against amyloid-beta peptide 1–
42 mediated toxicity and, thus, is nutritional candidate for
interventioninAD[12,45,46].Resveratrol,aswell,isamong
thepotentialsupplementsforADviamanipulationtargeting
activation of the Sirt-/PGC-1 neuroprotective axis [19, 47].
Other supplements and cocktails are recommended in other
studies and reviews.
Mimetics of environmental stress, in the seemingly unre-
lated phenomena, hibernation, exercise, heat attack, stroke,
severe hemorrhagic stroke trauma, metabolic diseases, and
neurological disorders and AD, share common denomina-
tors, ischemic, metabolic, protein misfolding, and oxidative
stress. The induction of protective pathways that promote
survival instead of apoptosis and cell death, associated
with energy deﬁcits and inﬂammatory processes share drug
beneﬁts despite the disparity in the acute and chronic disease
states. Diabetes drugs then may have potential for AD
therapy.
6. Telomeres, Aging, andAlzheimer’s Disease
Telomeraseisaribonucleoproteinpolymerasethatmaintains
telomere ends by the addition of the telomere repeat,
TTAGGG, that declines with age. Telomerase and telomeres
are the subject of thousands of current studies and reviews
that link telomeres to aging and cancer. It is clear that
telomerase function is not restricted only to repair of lost
telomerelengthwithageandmayinteractwiththepolycomb
complex,thatimpactsvariousbiologicalprocesses,including
diﬀerentiation, maintenance of cell identity, cell prolifera-
tion, and stem-cell plasticity. Decline in telomere function
links mitochondria, stem cells, and metabolic compromise
[48, 49].
Genetically engineered telomerase-deﬁcient mice are a
model system that shows in vivo wide-spread endoge-
nous DNA damage, tissue atrophy, stem-cell depletion,
organ system failure and impaired tissue response that
mimic age-related changes. The reversal of tissue degen-
eration in aged telomerase-deﬁcient mice by genetically
engineered inducible telomerase activation shows unprece-
dented evidence for global regeneration of organ systems
[50]. Telomerase reactivation in late generation TERT-ER
mice rejuvenates mice. The telomerase induction extends
telomeres, reduces DNA damage, associated cellular check-
point responses, restores proliferation in quiescent cultures,4 International Journal of Alzheimer’s Disease
eliminates degenerative phenotypes across multiple organs,
reverses neurodegeneration, and restores the innate behav-
ioral olfactory avoidance responses [50]. Evidence, that such
regeneration occurs in normal aging with activation of
telomerase, is, as yet, not available. The role of telomerase
and cancer is still unraveling; mimics of UV irradiation,
telomere oligonucleotides, induce apoptosis in malignant
but not normal cells [16]a n do ﬀer an anticancer potential
for telomere damage response.
Longer telomere length usually correlates with positive
survival response and stress resistance [51]. However telom-
ere shortening reduces amyloid brain pathology in mice [52]
and mole rats, a rodent model of successful aging, does
not show age-related disease vulnerability, and has short
telomeres [53].
The role of telomeres in aging and disease is of major
importance as knowledge of operative mechanisms unravel
in normal and disease states. At present, telomerase induc-
tion appears as an antiaging and rejuvenation potential that
may delay vulnerability to AD; however, it is too premature
to predict beneﬁts and adverse side eﬀects of treatment.
Activation of stem cell repair is a projected pathway with
advantage potential for AD.
7. Senescence versus Rejuvenation
The antithesis of telomerase promotion of cell replication
and growth is the p16INK4 locus involved in promotion of
senescence. The Ink4a/Arf locus encodes 2 tumor suppressor
molecules, p16INK4a and Arf, considered the principal
mediators of cellular senescence [54, 55]. Expression of
p16INK4a and Arf markedly increases in almost all rodent
tissues with advancing age, while there is little or no change
in the expression of other related cell cycle inhibitors. The
age-related increase in Ink4a/Arf expression can be inde-
pendently attributed to the expression of Ets-1, a known
p16INK4a transcriptional activator, as well as unknown
Ink4a/Arf coregulatory molecules [54, 55]. Genetic data have
ﬁrmly established that both p16INK4a and ARF proteins
possess signiﬁcant in vivo tumor suppressor activity. The
anti-cancer growth inhibitory activity of the p16INK4a and
ARF locus that can arrest cell growth beneﬁt unfortunately
can arrest cell growth in cells possessing self-renewal poten-
tial like tissue stem cells with a resulting decline the regen-
erative capabilities of the organ maintained by that stem
cell. Decline of this stem cell reserve is a cardinal feature of
mammalianaging marking the expression of the INK4a/ARF
locus, not only to be a major suppressor of cancer, but also
an eﬀecter of mammalian aging [54]. Mimetics that tips
the balance between INKA and telomerase, without cancer
promotion, are candidates for successful aging. There is
already evidence that the replicative state of the cell, normal
or cancer, can determine response to telomerase induction
[16] .T h et e l o m e r a s eg l o b a lp o t e n t i a li s ,a to n c e ,a w e s o m e
and frightening; evidence is that aside from extension of
telomeres, telomerase is a master regulator with potential for
regulation of hundreds of genes with unknown immediate
or long-term adverse side eﬀects on nondividing brain cells
in normal human aging. The telomere long length and
telomerase rejuvenation potential, though highly correlated
with longevity, can be independent, as found in the mole rat
short telomeres with long life.
8.SuccessfulAgingModel
In contrast with the multiple mouse models of disease
and age-accelerated systems, the naked mole rat, living in
burrows in arid and semiarid burrows in Africa, represents
a model of successful aging. The mole rats are the longest-
living rodents known, with a maximum lifespan of 30
years, at least 5 times or longer than expected on the basis
of body size [53]. For at least 80% of their life, mole
rats maintain normal activity, body composition, repro-
ductive and physiological functions with no obvious age-
related increases in morbidity or mortality rate, and cancer
resistance. Surprisingly, the mole rats have high levels of
oxidative stress and relatively short telomeres, yet they are
extremely resilient when subjected to cellular stressors and
appear capable of sustaining both their genomic and protein
integrity under hostile conditions [56] .T h er e s i s t a n c eo f
mole rats to oxidative stress suggests resistance neurological
damage. Hypoxic stress by nutrient oxygen deprivation in
hippocampalslicesofnakedmoleratshowsthatneuraltissue
is resistant to nutrient oxygen deprivation [56]a n dl i k e l y
resistance to AD toxicity. Neuregulin-1 (NRG-1) signaling,
critical for normal brain function during both development
and adulthood, is sustained throughout development and
adulthoodinmolerat[57].Moreover,meanlifespanstrongly
correlated with levels of NRG-1, and its receptor, linking
lifespan and NRG-1 levels. Neuregulin becomes a candidate
target molecule for modulation, and the mole rat, a model
organism for AD research.
9. Immunological Therapy and
InnateImmunity
The major focus of Alzheimer’s research is the attractive
immunological therapeutic intervention approach to AD.
Over 25,000 articles report the progress and perils of
immunotherapy in treatment of AD as the focus of phar-
maceutical drug discovery. Like induction of stress response
to combat the disease challenge, induction of the immune
response activates defenses to intervene in AD. Multiple
reviewsareavailableonthetopic,andonlyabriefdescription
of this valuable therapeutic approach is included here. An
immunological solution has proven to be elusive, complex,
costly, and ineﬀective so far, as the studies of the last
decade reveal. Lessons learned include the discovery that
although immunization of Amyloid β (Aβ)p e p t i d ec o u l d
protect and reverse amyloid pathology in animal models, in
human trials, although immunotherapy did clear amyloid
plaques, the clearance did not show a cognitive beneﬁt eﬀect
in AD patients [58]. The amyloid hypothesis, as a target
for AD immunotherapy, is at the crossroads [59]. Hope
for (Aβ) vaccines remains, since a subset of patients with
antibody titers in the active vaccine study, showed signs ofInternational Journal of Alzheimer’s Disease 5
cognitive stabilization [60]. Adverse eﬀects resulted in the
discontinuance of human trials in an active vaccine study
including meningoencephalitis with AN1792, vasogenic
edema,andmicrohemorrhageswithbapineuzumab,andun-
certain results of cognitive beneﬁt using passive (Aβ)
immunotherapyinageneticsubgroupcarriersoftheAPOE4
gene[61].Newgenerationvaccinesagainst(Aβ)peptide,and
tau protein, may avoid adverse side eﬀects, and slow progres-
sion of cognitive loss. The further reﬁnement of AD DNA
epitope vaccines is another immunological approach with
promise for clinical trials administered preferably in preclin-
ical stage individuals identiﬁed by validated AD biomarkers
[62]. Unfortunately, agreement on the underlying cause(s)
of AD is not established nor is the optimal immunological
target(s).
An alternative immune therapy approach is the acti-
vation of innate immune function conserved throughout
evolution, present in ancient organisms, and inducible in
humans that does not require the knowledge of the causative
agent of AD; rather activates a generalized resistance state.
The preserved ancient immune T-cell immunoregulator, the
CDR1 peptide of sharks, elicits an immune response in
higher organisms and humans. The CDR1 peptide is in-
volvedinhomeostasis,immunoregulation,responsetoinfec-
tion, and reversal of the negative eﬀects of immunosenes-
cence on normal TH1 and TH2 T-cell subsets [63]. The TCR
peptide itself restores balance between TH1 and TH2 and
stimulates cells remodeling defective heart tissue implicating
a role for immune system in cardiac repair [64]. The reversal
of immunosenescence may directly impact the vulnerability
of elderly to AD, or even provide repair after AD onset.
Another ancient immune factor is “the unmethylated
CpG motifs,” found to be prevalent in bacterial but not ver-
tebrategenomic DNAs [65]. Oligodeoxynucleotides contain-
ing CpG motifs activate host defense mechanisms leading
to innate and acquired immune responses. The recognition
of CpG motifs requires the toll-like receptor. CpG-induced
activation of innate immunity protects against lethal chal-
lenge from a wide variety of pathogens and has therapeutic
activity in murine models of cancer and allergy. CpG motifs
alsoenhancethedevelopmentofacquiredimmuneresponses
for prophylactic and therapeutic vaccination [65]a n dm a y
boost immune function in AD vaccinations.
10. Stress Response Activation:
Timing and Delivery
The optimal timing of intervention with alternative trigger
induction strategies, intuitively, is prior to the onset of
disease in known vulnerable candidates (early onset genetic
predisposition, the elderly, prior history of brain damage),or
intheearlyphaseswhenthereisdetectionofADbiomarkers,
as is the preferred treatment population for all AD inter-
ventions. It is easier to prevent damage, rather than repair
damage. However, there is promise for intervention in later
stages of AD for delay of progression, or even reversal using
triggers of stress resistance by upregulation of tolerance and
rejuvenation after damage has occurred in other disease
models, as outlined in the references presented above, for use
in all stages of AD progression to delay progression or even
reverse symptoms.
In theory, the delivery of mimetics of stress resistance
triggers may be by oral, venous injection, or intranasal, since
these delivery modes have been used to activate protective
and rejuvenation response in rodent models, and in some
cases to treat inﬂammatory human diseases. Especially
promising is the use of intranasal delivery in neurodegener-
ative diseases and stroke [66]. Direct access to the damage
brain tissue is attractive and may avoid other potential
adverse eﬀects by system-wide treatment.
From the above discussions, the theoretical beneﬁts of
the stress response triggers after disease onset include (1)
the upregulation of protective mechanism to restore protein
structure, using the inducers of chaperone proteins HSP’s;
(2) reduction of the increased inﬂammatory response to the
disease states, and oxidative damage cascades, using hiber-
nation like opioid mimetics, innate immune triggers, and
endogenous antioxidant element triggers, to protect against
further damage; (3) restoration of metabolic homeostasis,
proteostasis, and antioxidant protection with the exercise
mimetic, AICAR [43]. Cognitive function requires rejuve-
nation and repair, reduction of cell death, and induction of
Nerve Growth Factors found in cells after AICAR treatment.
Theoretically, the vision is that induction of stress
resistance will delay or stop the progression of the disease
and even restore cognitive function. More than one trigger
may be required, and/or the strategy of induction of stress
resistance may be a valuable addition in genetic subpopula-
tions resistant to immune therapies. Lessons learned from
history teach us that theory and practice do not always
coincide. Until appropriate controlled human clinical trials
are explored and analyzed, the actual beneﬁt of the proposed
strategy remains unknown.
11. Conclusion
Mimetics of chemical and environmental stress can provide
valuable activation of protective pathways with potential in
intervention in the pathologies of AD now. The advantages
of the activation of stress resistance as alternative strategy
include availability, without new drug development, and,
in some cases, triggers are already in human use to treat
other metabolic, ischemic, and inﬂammatory disease con-
ditions and pathologies. There is real hope for multiple
options in AD intervention drugs presently in testing,
alone or in combination with other therapies, especially in
genetic subpopulations resistant to immunotherapy or other
approaches.
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